Autism spectrum disorder (ASD) comprises a group of neurodevelopmental disorders characterized by social deficits and stereotyped behaviors. While several theories have emerged, the pathogenesis of ASD remains unknown. Although studies report dopamine signaling abnormalities in autistic patients, a coherent dopamine hypothesis which could link neurobiology to behavior in ASD is currently lacking. In this paper, we present such a hypothesis by proposing that autistic behavior arises from dysfunctions in the midbrain dopaminergic system. We hypothesize that a dysfunction of the mesocorticolimbic circuit leads to social deficits, while a dysfunction of the nigrostriatal circuit leads to stereotyped behaviors. Furthermore, we discuss 2 key predictions of our hypothesis, with emphasis on clinical and therapeutic aspects. First, we argue that dopaminergic dysfunctions in the same circuits should associate with autistic-like behavior in nonautistic subjects. Concerning this, we discuss the case of PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections) which displays behaviors similar to those of ASD, presumed to arise from dopaminergic dysfunctions. Second, we argue that providing dopamine modulators to autistic subjects should lead to a behavioral improvement. Regarding this, we present clinical studies of dopamine antagonists which seem to have improving effects on autistic behavior. Furthermore, we explore the means of testing our hypothesis by using neuroreceptor imaging, which could provide comprehensive evidence for dopamine signaling dysfunctions in autistic subjects. Lastly, we discuss the limitations of our hypothesis. Along these lines, we aim to provide a dopaminergic model of ASD which might lead to a better understanding of the ASD pathogenesis.

Keywords:
Autism, Dopamine, Hypothesis, Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections, Dopamine antagonists
1.
American Psychiatric Association: Autism spectrum disorder, 299.00 (F84.0); in: Diagnostic and statistical manual of mental disorders: DSM-5, ed 5. Washington DC, APA, 2013.
2.
de la Torre-Ubieta L, Won H, Stein JL, Geschwind DH: Advancing the understanding of autism disease mechanisms through genetics. Nat Med 2016;22:345-361.
3.
King BH, Lord C: Is schizophrenia on the autism spectrum? Brain Res 2011;1380:34-41.
4.
Scott-Van Zeeland AA, Dapretto M, Ghahremani DG, Poldrack RA, Bookheimer: Reward processing in autism. Autism Res 2010;3:53-67.
5.
Ernst M, Zametkin AJ, Matochik JA, Pascualvaca D, Cohen RM: Low medial prefrontal dopaminergic activity in autistic children. Lancet 1997;350:638.
6.
Dichter GS, Felder JN, Green SR, Rittenberg AM, Sasson NJ, Bodfish JW: Reward circuitry function in autism spectrum disorders. Soc Cogn Affect Neurosci 2012;7:160-172.
7.
Dichter GS, Damiano CA, Allen JA: Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings. J Neurodev Disord 2012;4:4-19.
8.
Haber SN: The place of dopamine in the cortico-basal ganglia circuit. Neuroscience 2014;282C:248-257.
9.
Bear M, Connors B, Paradiso M: Chemical control of the brain and the behavior; in: Neuroscience: Exploring the Brain. Philadelphia, Lippincott Williams and Wilkins 2007.
10.
Sydor A, Brown R: Widely projecting systems: monoamines, acetylcholine, and orexin; in Nestler EJ, Hyman SE, Malenka RC (eds): Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, ed 2. New York, McGraw-Hill Medical, 2001.
11.
Chevallier C, Kohls G, Troiani V, Brodkin ES, Schultz RT: The social motivation theory of autism. Trends Cogn Sci 2012;16:231-239.
12.
Dichter GS, Richey JA, Rittenberg AM, Sabatino A, Bodfish JW: Reward circuitry function in autism during face anticipation and outcomes. J Autism Dev Disord 2012;42:147-160.
13.
Damiano CR, et al: Association between the oxytocin receptor (OXTR) gene and mesolimbic responses to rewards. Mol Autism 2014;5:7.
14.
Anagnostou E, Soorya L, Brian J, Dupuis A, Mankad D, Smile S, Jacob S: Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res 2014;1580:188-198.
15.
Damiano CR, Aloi J, Treadway M, Bodfish JW, Dichter GS: Adults with autism spectrum disorders exhibit decreased sensitivity to reward parameters when making effort-based decisions. J Neurodev Disord 2012;4:4-13.
16.
Lewis M, Soo-Jeong K: The pathophysiology of restricted repetitive behavior. J Neurodev Disord 2009;1:114-132.
17.
Lewis M, et al: Animal models of restricted repetitive behavior in autism. Behav Brain Res 2007;176:66-74.
18.
Presti MF, Mikes HM, Lewis MH: Selective blockade of spontaneous motor stereotypy via intrastriatal pharmacological manipulation. Pharmacol Biochem Behav 2003;74:833-839.
19.
Horev G, Ellegood J, Lerch JP, et al: Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism. Proc Natl Acad Sci USA 2011;108:17076-17081.
20.
Staal WG: Autism, DRD3 and repetitive and stereotyped behavior, an overview of the current knowledge. Eur Neuropsychopharmacol 2015;25:1421-1426.
21.
Staal WG, Langen M, van Dijk S, Mensen VT, Durston S: DRD3 gene and striatum in autism spectrum disorder. Br J Psychiatry 2015;206:431-432.
22.
Gadow KD, Devincent CJ, Olvet DM, Pisarevskaya V, Hatchwell E: Association of DRD4 polymorphism with severity of oppositional defiant disorder, separation anxiety disorder and repetitive behaviors in children with autism spectrum disorder. Eur J Neurosci 2010;32:1058-1065.
23.
Murphy TK, Gerardi DM, Leckman JF: Pediatric acute-onset neuropsychiatric syndrome. Psychiatr Clin North Am 2014;37:353-374.
24.
Williams KA, Swedo SE: Post-infectious autoimmune disorders: Sydenham's chorea, PANDAS and beyond. Brain Res 2015;1617:144-154.
25.
Orefici G, Cardona F, Cox CJ, et al: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS); in Ferretti JJ, Stevens DL, Fischetti VA (eds): Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City, University of Oklahoma Health Sciences Center, 2016.
26.
Kirvan CA, Swedo SE, Snider LA, Cunningham MW: Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol 2006;179:173-179.
27.
Yamauchi T: Neuronal Ca2+/calmodulin-dependent protein kinase II - discovery, progress in a quarter of a century, and perspective: implication for learning and memory. Biol Pharm Bull 2005;28:1342-1354.
28.
Liu XY, Mao LM, Zhang GC, et al: Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. Neuron 2009;61:425-438.
29.
de Krom M, Staal WG, Ophoff RA, et al: A common variant in DRD3 receptor is associated with autism spectrum disorder. Biol Psychiatry 2009;65:625-630.
30.
De Rubeis S, Bagni C: Regulation of molecular pathways in the Fragile X syndrome: insights into autism spectrum disorders. J Neurodev Disord 2011;3:257-269.
31.
Canitano R: Self-injurious behavior in autism: clinical aspects and treatment with risperidone. J Neural Transm 2006;113:425−431.
32.
Toda Y, Mori K, Hashimoto T, et al: Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev 2006;28:99−103.
33.
Toda M, Abi-Dargham A: Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 2007;9:329-336.
34.
LeClerc S, Easley D: Pharmacological therapies for autism spectrum disorder: a review. Pharm Ther 2015;40:389-397.
35.
McCracken JT, et al: Risperidone in children with autism and serious behavioral problems. N England J Med 2002;347:314-321.
36.
McDougle CJ, et al: Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 2005;162:1142-1148.
37.
Ghaeli P, et al: Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study. Indian J Psychol Med 2014;36:66-70.
38.
Scahill L, et al: Brief report: social disability in autism spectrum disorder: results from research units on pediatric psychopharmacology (RUPP) autism network trials. J Autism Dev Disord 2013;43:739-746.
39.
Kazdoba TM, Leach PT, Yang M, Silverman JL, Solomon M, Crawley JN: Translational mouse models of autism: advancing toward pharmacological therapeutics. Curr Top Behav Neurosci 2016;28:1-52.
40.
Salavati B, Rajji TK, Price R, Sun Y, Graff-Guerrero A, Daskalakis ZJ: Imaging-based neurochemistry in schizophrenia: a systematic review and implications for dysfunctional long-term potentiation. Schizophr Bull 2015;41:44-56.
41.
Zürcher NR, Bhanot A, McDougle CJ, Hooker JM: A systematic review of molecular imaging (PET and SPECT) in autism spectrum disorder: current state and future research opportunities. Neurosci Biobehav Rev 2015;52:56-73.
42.
Heal DJ, Smith SL, Gosden J, Nutt DJ: Amphetamine, past and present - a pharmacological and clinical perspective. J Psychopharmacol 2013;27:479-496.
43.
Müller RA: The study of autism as a distributed disorder. Ment Retard Dev Disabil Res Rev 2007;13:85-95.
44.
Masi A, et al: An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull 2017;33:183-193.
45.
Gadow KD, et al: Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder. J Child Psychol Psychiatry 2008;49:1331-1338.
46.
Nieoullon A: Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
47.
Yang P, Chang CL: Glutamate-mediated signaling and autism spectrum disorders: emerging treatment targets. Curr Pharm Des 2014;20:5186-5193.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.